Indeed, the treatment of advanced stage NSCLC has evolved from the empiric use of chemotherapy to a armamentarium of tailored approaches, with subsets of patients treated according to the genetic alterations of their tumor and the status of programmed death ligand-1 (PD-L1), which predict the response to targeted therapies or immune checkpoint inhibitors, respectively [4]. Here, CD274 is linked to non-small cell lung carcinoma.